Ypsomed (SIX: YPSN) will expand its offering of digital health solutions together with S3 Connected Health in the future. S3 Connected Health, headquartered in Dublin, Ireland is a specialist digital health partner for life science companies. The new offering will allow Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. People with acute and chronic diseases can thus be supported fully in their therapy management and the outcome of their treatment can be enhanced.
Digital health solutions play an increasingly important role in how well patients with acute and chronic diseases manage their therapy. To further drive this development Ypsomed partners with S3 Connected Health to create an extendable platform for the creation of specific solutions that provide patients with support and guidance throughout their therapy. Ypsomed’s connected injection devices such as the SmartPilot for YpsoMate are pre-integrated in the platform. The platform is highly versatile and quick to customize for any disease area and use case – always with the aim to provide additional value to patients.
“The new platform will enable our Pharma and Biotech customers to rapidly launch integrated device and
digital health solutions that will further improve therapy outcomes and quality of life for their patients. This
new product offering complements our existing product portfolio and partnerships in the connected device
and digital health area. It will help us to strengthen our position in this space and provide our customers with
the best possible value”, explains Ulrike Bauer, Chief Business Officer Delivery Systems.
Ypsomed’s offering is powered by S3 Connected Health’s Affinial Platform, the most comprehensive platform for life science companies to create regulated digital health solutions. Affinial is designed to power digital health applications and use cases by encoding over 20 years’ experience of best practice in delivery of digital health at scale. Since Affinial was launched it has established itself as the leading platform for life sciences companies.
The new platform offering includes a patient application, a clinical system, a Patient Support Portal and analytical dashboard with real-time access to anonymized data. Alongside pre-integration of Ypsomed’s device portfolio, the platform provides a range of features around self-injection, incorporates behavioral science mechanisms to ensure high levels of engagement, and personalization of the application to users’ needs.
“We look forward to collaborating closely with Ypsomed to achieve our shared vision of improving patients’ lives. Our Affinial platform and deep expertise in creating and operating regulated digital health solutions is a perfect fit with Ypsomed’s drive for innovation and highest quality” says Jim O’Donoghue, President of S3 Connected Health.
The new product offering will be marketed through Ypsomed and will be offered to customers in collaboration with S3 Connected Health for customization to serve their specific use cases and brand.
Contact
Grainne O'Reilly
Senior Marketing Manager
S3 Connected Health
+353 1 563 2125
grainne.oreilly@s3connectedhealth.com
Ypsomed Group
Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years of experience. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brands mylife diabetes care directly to patients or via pharmacies and hospitals as well
as under YDS Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. The company is headquartered in Burgdorf, Switzerland, and has a global network of production facilities, subsidiaries and distribution partners employing a staff of over 2,000 employees worldwide.
www.ypsomed.com
S3 Connected Health
S3 Connected Health is the specialist digital health partner for life science companies, developing regulated digital health solutions that improve the lives of people with acute and chronic conditions. It has delivered award-winning, regulatory-compliant solutions across 20 therapy areas and in more than 50 countries. The company's scalable and secure solutions improve disease management, differentiate pharmaceutical
products and deliver new therapeutic approaches. Affinial, S3 Connected Health's digital health platform, offers partners the opportunity to develop customized digital health solutions tailored to specific patient, device or disease needs. The platform’s pre-built services can be customized and implemented with reduced costs and shorter time-to-market. www.s3connectedhealth.com
S3 Connected Health
South County Business Park, Leopardstown
Dublin 18
Ireland